Important Notice
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report published in designated media by the China Securities Regulatory Commission. All directors attended the board meeting to review this report. The audit opinion from Beijing Dehao International Accounting Firm (Special General Partnership) on this year's financial report is: unable to express an opinion.
Non-standard audit opinion: ☒ Applicable □ Not applicable
The audit opinion from Beijing Dehao International Accounting Firm (Special General Partnership) on this year's financial report is: unable to express an opinion.
The company was not profitable at the time of listing and has not achieved profitability currently: □ Applicable ☒ Not applicable
The profit distribution plan or capital reserve transfer to increase share capital reviewed by the board during the reporting period: □ Applicable ☒ Not applicable
The company plans not to distribute cash dividends, issue bonus shares, or transfer capital reserves to increase share capital.
The board resolution approved the preferred stock profit distribution plan for this reporting period: ☒ Applicable □ Not applicable
Company Overview
-
Company Profile
- Stock Abbreviation: *ST Jiyuan
- Stock Code: 300108
- Stock Exchange: Shenzhen Stock Exchange
- Contact Person:
- Secretary of the Board: Zhang Liang
- Securities Affairs Representative: Wang Yan
- Office Address: No. 6, Huan Cheng North Road, Meihekou City, Jilin Province
- Fax: 0435-3751886
- Phone: 0435-3752903
- Email: zhangliang300108@163.com, wangyan300108@163.com
-
Main Business or Product Overview
The company primarily focuses on the pharmaceutical health industry, forming a group enterprise that includes pharmaceutical manufacturing, pharmaceutical commerce (including drug retail), pharmaceutical research and development, medical care, and pharmaceutical industry investment. The pharmaceutical manufacturing segment mainly produces traditional Chinese and Western medicines, biopharmaceuticals, and health foods, covering 15 dosage forms including tablets, capsules, and injections. The company currently holds approximately 128 drug production licenses, including national medical insurance products. -
Key Accounting Data and Financial Indicators
(1) Main Accounting Data and Financial Indicators for the Past Three Years
The company does not need to restate previous years' accounting data: □ Yes ☒ No